Compare BridgeBio Pharma Inc (BBIO) vs Vanguard Total Stock Market Index Fund ETF (VTI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Vanguard Total Stock Market Index Fund ETF — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Vanguard Total Stock Market Index Fund ETF trades at $381.43. The key difference: Vanguard Total Stock Market Index Fund ETF is trading nearer its 52-week high, BridgeBio Pharma Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | VTI | |
|---|---|---|
Market Cap | $16.61B | — |
Sector | Health | — |
52-Week High | $90.17 | $381.78 |
52-Week Low | $47.29 | $311.68 |
Enterprise Value | $18.16B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
VTI trades at $381.78, up 0.71% with strong bullish momentum indicated by moving averages. The ETF shows institutional accumulation with multiple firms increasing positions in Q2 2026. Technical indicators show mixed signals with RSI suggesting potential overbought conditions while ADX confirms strong trend strength. Recent news highlights VTI's role as a core portfolio holding for long-term investors seeking broad market exposure.
VTI offers diversified US equity exposure with low-cost structure, though recent fee competition from competitors like BBUS presents margin pressure. The ETF's 14.53% 10-year annualized return demonstrates strong historical performance. Key risks include market concentration in large-cap tech and broader economic sensitivity. Analyst sentiment remains positive for long-term investors seeking total market diversification.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Vanguard Total Stock Market Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the index, which represents approximately 100% of the investable US stock market and includes large-, mid-, small-, and micro-cap stocks. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the full index in terms of key characteristics.
Read more on VTI →
